{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:11:49Z","timestamp":1788775909716,"version":"build-2803163510"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,23]]},"DOI":"10.7759\/cureus.102160","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:00:12Z","timestamp":1769191212000},"source":"Crossref","is-referenced-by-count":3,"title":["Metabolic Inflammation as a Common Thread in Cardio-Endocrine Diseases: Toward a Unified Therapeutic Framework"],"prefix":"10.7759","author":[{"given":"Nidhi","family":"Patil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Uppal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simranjeet","family":"Bedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiral","family":"Undhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100960","article-title":"Cardiovascular disease in the Americas: the epidemiology of cardiovascular disease and its risk factors","volume":"42","author":"Joseph P","year":"2025","unstructured":"Joseph P, Lanas F, Roth G, et al.. Cardiovascular disease in the Americas: the epidemiology of cardiovascular disease and its risk factors. Lancet Reg Health Am. 2025, 42:100960. 10.1016\/j.lana.2024.100960","journal-title":"Lancet Reg Health Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0329023","article-title":"Machine learning-based predictive modeling of angina pectoris in an elderly community-dwelling population: results from the PoCOsteo study","volume":"20","author":"Mousavi S","year":"2025","unstructured":"Mousavi S, Jalalian Z, Afrashteh S, Farhadi A, Nabipour I, Larijani B. Machine learning-based predictive modeling of angina pectoris in an elderly community-dwelling population: results from the PoCOsteo study. PLoS One. 2025, 20:e0329023. 10.1371\/journal.pone.0329023","journal-title":"PLoS One"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_212_17","article-title":"The heart of the matter: cardiac manifestations of endocrine disease","volume":"21","author":"Binu AJ","year":"2017","unstructured":"Binu AJ, Cherian KE, Kapoor N, Chacko ST, George O, Paul TV. The heart of the matter: cardiac manifestations of endocrine disease. Indian J Endocrinol Metab. 2017, 21:919-25. 10.4103\/ijem.IJEM_212_17","journal-title":"Indian J Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.02.003","article-title":"The global burden of metabolic disease: data from 2000 to 2019","volume":"35","author":"Chew NW","year":"2023","unstructured":"Chew NW, Ng CH, Tan DJ, et al.. The global burden of metabolic disease: data from 2000 to 2019. Cell Metab. 2023, 35:414-28.e3. 10.1016\/j.cmet.2023.02.003","journal-title":"Cell Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-015-0268-9","article-title":"The economic costs of type 2 diabetes: a global systematic review","volume":"33","author":"Seuring T","year":"2015","unstructured":"Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics. 2015, 33:811-31. 10.1007\/s40273-015-0268-9","journal-title":"Pharmacoeconomics"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2337\/dci23-0085","article-title":"Economic costs of diabetes in the U.S. in 2022","volume":"47","author":"Parker ED","year":"2024","unstructured":"Parker ED, Lin J, Mahoney T, et al.. Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2024, 47:26-43. 10.2337\/dci23-0085","journal-title":"Diabetes Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.18502\/ijph.v52i1.11673","article-title":"Economic impacts of cardiovascular diseases: an econometric evaluation in Turkey","volume":"52","author":"Ekinci G","year":"2023","unstructured":"Ekinci G. Economic impacts of cardiovascular diseases: an econometric evaluation in Turkey. Iran J Public Health. 2023, 52:118-27. 10.18502\/ijph.v52i1.11673","journal-title":"Iran J Public Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5806-x","article-title":"The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review","volume":"18","author":"Gheorghe A","year":"2018","unstructured":"Gheorghe A, Griffiths U, Murphy A, Legido-Quigley H, Lamptey P, Perel P. The economic burden of cardiovascular disease and hypertension in low- and middle-income countries: a systematic review. BMC Public Health. 2018, 18:975. 10.1186\/s12889-018-5806-x","journal-title":"BMC Public Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.908749","article-title":"The roles of adipose tissue macrophages in human disease","volume":"13","author":"Liang W","year":"2022","unstructured":"Liang W, Qi Y, Yi H, Mao C, Meng Q, Wang H, Zheng C. The roles of adipose tissue macrophages in human disease. Front Immunol. 2022, 13:908749. 10.3389\/fimmu.2022.908749","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1172\/JCI19246","article-title":"Obesity is associated with macrophage accumulation in adipose tissue","volume":"112","author":"Weisberg SP","year":"2003","unstructured":"Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003, 112:1796-808. 10.1172\/JCI19246","journal-title":"J Clin Invest"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cells11050844","article-title":"Molecular mechanism of lipotoxicity as an interesting aspect in the development of pathological states-current view of knowledge","volume":"11","author":"Lipke K","year":"2022","unstructured":"Lipke K, Kubis-Kubiak A, Piwowar A. Molecular mechanism of lipotoxicity as an interesting aspect in the development of pathological states-current view of knowledge. Cells. 2022, 11:844. 10.3390\/cells11050844","journal-title":"Cells"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.07.005","article-title":"Lipid regulation of NLRP3 inflammasome activity through organelle stress","volume":"42","author":"Liang JJ","year":"2021","unstructured":"Liang JJ, Fraser ID, Bryant CE. Lipid regulation of NLRP3 inflammasome activity through organelle stress. Trends Immunol. 2021, 42:807-23. 10.1016\/j.it.2021.07.005","journal-title":"Trends Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02379","article-title":"Pattern recognition receptors and the host cell death molecular machinery","volume":"9","author":"Amarante-Mendes GP","year":"2018","unstructured":"Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018, 9:2379. 10.3389\/fimmu.2018.02379","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2015.01.008","article-title":"NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases","volume":"4","author":"Abderrazak A","year":"2015","unstructured":"Abderrazak A, Syrovets T, Couchie D, El Hadri K, Friguet B, Simmet T, Rouis M. NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol. 2015, 4:296-307. 10.1016\/j.redox.2015.01.008","journal-title":"Redox Biol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/cells7060063","article-title":"Endoplasmic reticulum stress in metabolic disorders","volume":"7","author":"Ghemrawi R","year":"2018","unstructured":"Ghemrawi R, Battaglia-Hsu SF, Arnold C. Endoplasmic reticulum stress in metabolic disorders. Cells. 2018, 7:63. 10.3390\/cells7060063","journal-title":"Cells"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12170-012-0280-y","article-title":"Systems biology approaches and applications in obesity, diabetes, and cardiovascular diseases","volume":"7","author":"Meng Q","year":"2013","unstructured":"Meng Q, M\u00e4kinen VP, Luk H, Yang X. Systems biology approaches and applications in obesity, diabetes, and cardiovascular diseases. Curr Cardiovasc Risk Rep. 2013, 7:73-83. 10.1007\/s12170-012-0280-y","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/biom15030373","article-title":"Cardiovascular-endocrine-metabolic medicine: proposing a new clinical sub-specialty amid the cardiometabolic pandemic","volume":"15","author":"Theodorakis N","year":"2025","unstructured":"Theodorakis N, Nikolaou M, Krentz A. Cardiovascular-endocrine-metabolic medicine: proposing a new clinical sub-specialty amid the cardiometabolic pandemic. Biomolecules. 2025, 15:373. 10.3390\/biom15030373","journal-title":"Biomolecules"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01937-x","article-title":"The cardio-renal-metabolic connection: a review of the evidence","volume":"22","author":"Marassi M","year":"2023","unstructured":"Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023, 22:195. 10.1186\/s12933-023-01937-x","journal-title":"Cardiovasc Diabetol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2018.01.119","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial","volume":"10","author":"Thompson PL","year":"2018","unstructured":"Thompson PL, Nidorf SM. Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial. J Thorac Dis. 2018, 10:695-8. 10.21037\/jtd.2018.01.119","journal-title":"J Thorac Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-024-06306-1","article-title":"Targeting the NLRP3 inflammasome-IL-1\u03b2 pathway in type 2 diabetes and obesity","volume":"68","author":"Meier DT","year":"2025","unstructured":"Meier DT, de Paula Souza J, Donath MY. Targeting the NLRP3 inflammasome-IL-1\u03b2 pathway in type 2 diabetes and obesity. Diabetologia. 2025, 68:3-16. 10.1007\/s00125-024-06306-1","journal-title":"Diabetologia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.334","article-title":"Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial","volume":"170","author":"Wing RR","year":"2010","unstructured":"Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010, 170:1566-75. 10.1001\/archinternmed.2010.334","journal-title":"Arch Intern Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/802078","article-title":"The role of adipose tissue and adipokines in obesity-related inflammatory diseases","volume":"2010","author":"Balistreri CR","year":"2010","unstructured":"Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm. 2010, 2010:802078. 10.1155\/2010\/802078","journal-title":"Mediators Inflamm"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.2337\/db08-0872","article-title":"Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes","volume":"57","author":"Lumeng CN","year":"2008","unstructured":"Lumeng CN, DelProposto JB, Westcott DJ, Saltiel AR. Phenotypic switching of adipose tissue macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes. 2008, 57:3239-46. 10.2337\/db08-0872","journal-title":"Diabetes"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi N","year":"2011","unstructured":"Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011, 11:85-97. 10.1038\/nri2921","journal-title":"Nat Rev Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M500294-JLR200","article-title":"Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans","volume":"46","author":"Cinti S","year":"2005","unstructured":"Cinti S, Mitchell G, Barbatelli G, et al.. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005, 46:2347-55. 10.1194\/jlr.M500294-JLR200","journal-title":"J Lipid Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/35053000","article-title":"The hormone resistin links obesity to diabetes","volume":"409","author":"Steppan CM","year":"2001","unstructured":"Steppan CM, Bailey ST, Bhat S, et al.. The hormone resistin links obesity to diabetes. Nature. 2001, 409:307-12. 10.1038\/35053000","journal-title":"Nature"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01058.2004","article-title":"Adipokines: molecular links between obesity and atheroslcerosis","volume":"288","author":"Lau DC","year":"2005","unstructured":"Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005, 288:H2031-41. 10.1152\/ajpheart.01058.2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0395","article-title":"Adipose tissue as an endocrine organ","volume":"89","author":"Kershaw EE","year":"2004","unstructured":"Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004, 89:2548-56. 10.1210\/jc.2004-0395","journal-title":"J Clin Endocrinol Metab"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-19186-2","article-title":"Association between metabolic score of visceral fat and carotid atherosclerosis in Chinese health screening population: a cross-sectional study","volume":"24","author":"Qian J","year":"2024","unstructured":"Qian J, Huang G, Mao Y. Association between metabolic score of visceral fat and carotid atherosclerosis in Chinese health screening population: a cross-sectional study. BMC Public Health. 2024, 24:1723. 10.1186\/s12889-024-19186-2","journal-title":"BMC Public Health"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20030","article-title":"Visceral fat resection in humans: effect on insulin sensitivity, beta-cell function, adipokines, and inflammatory markers","volume":"21","author":"Lima MM","year":"2013","unstructured":"Lima MM, Pareja JC, Alegre SM, et al.. Visceral fat resection in humans: effect on insulin sensitivity, beta-cell function, adipokines, and inflammatory markers. Obesity (Silver Spring). 2013, 21:E182-9. 10.1002\/oby.20030","journal-title":"Obesity (Silver Spring)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/nature07540","article-title":"A core gut microbiome in obese and lean twins","volume":"457","author":"Turnbaugh PJ","year":"2009","unstructured":"Turnbaugh PJ, Hamady M, Yatsunenko T, et al.. A core gut microbiome in obese and lean twins. Nature. 2009, 457:480-4. 10.1038\/nature07540","journal-title":"Nature"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.2337\/db06-1491","article-title":"Metabolic endotoxemia initiates obesity and insulin resistance","volume":"56","author":"Cani PD","year":"2007","unstructured":"Cani PD, Amar J, Iglesias MA, et al.. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007, 56:1761-72. 10.2337\/db06-1491","journal-title":"Diabetes"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/86.5.1286","article-title":"A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation","volume":"86","author":"Erridge C","year":"2007","unstructured":"Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr. 2007, 86:1286-92. 10.1093\/ajcn\/86.5.1286","journal-title":"Am J Clin Nutr"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang Z","year":"2011","unstructured":"Wang Z, Klipfell E, Bennett BJ, et al.. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011, 472:57-63. 10.1038\/nature09922","journal-title":"Nature"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2017.09.008","article-title":"Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition","volume":"26","author":"Kootte RS","year":"2017","unstructured":"Kootte RS, Levin E, Saloj\u00e4rvi J, et al.. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 2017, 26:611-619.e6. 10.1016\/j.cmet.2017.09.008","journal-title":"Cell Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath MY","year":"2011","unstructured":"Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011, 11:98-107. 10.1038\/nri2925","journal-title":"Nat Rev Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee M","year":"2001","unstructured":"Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414:813-20. 10.1038\/414813a","journal-title":"Nature"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein(a) in Alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: Mendelian randomization investigation","volume":"141","author":"Larsson SC","year":"2020","unstructured":"Larsson SC, Gill D, Mason AM, Jiang T, B\u00e4ck M, Butterworth AS, Burgess S. Lipoprotein(a) in Alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: Mendelian randomization investigation. Circulation. 2020, 141:1826-8. 10.1161\/CIRCULATIONAHA.120.045826","journal-title":"Circulation"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-22-0184","article-title":"NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners","volume":"257","author":"Leu SY","year":"2023","unstructured":"Leu SY, Tsang YL, Ho LC, et al.. NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners. J Endocrinol. 2023, 257:220184. 10.1530\/JOE-22-0184","journal-title":"J Endocrinol"},{"key":"ref40","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1108586108","article-title":"The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse","volume":"108","author":"Mezzaroma E","year":"2011","unstructured":"Mezzaroma E, Toldo S, Farkas D, et al.. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci USA. 2011, 108:19725-30.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2012.02517.x","article-title":"Increased interleukin-1\u03b2 levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention","volume":"272","author":"\u00d8rn S","year":"2012","unstructured":"\u00d8rn S, Ueland T, Manhenke C, et al.. Increased interleukin-1\u03b2 levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention. J Intern Med. 2012, 272:267-76. 10.1111\/j.1365-2796.2012.02517.x","journal-title":"J Intern Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2022","article-title":"Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling","volume":"12","author":"Wen H","year":"2011","unstructured":"Wen H, Gris D, Lei Y, et al.. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011, 12:408-15. 10.1038\/ni.2022","journal-title":"Nat Immunol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes","volume":"11","author":"Masters SL","year":"2010","unstructured":"Masters SL, Dunne A, Subramanian SL, et al.. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes. Nat Immunol. 2010, 11:897-904. 10.1038\/ni.1935","journal-title":"Nat Immunol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.309575","article-title":"NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice-brief report","volume":"37","author":"van der Heijden T","year":"2017","unstructured":"van der Heijden T, Kritikou E, Venema W, et al.. NLRP3 inflammasome inhibition by MCC950 reduces atherosclerotic lesion development in apolipoprotein E-deficient mice-brief report. Arterioscler Thromb Vasc Biol. 2017, 37:1457-61. 10.1161\/ATVBAHA.117.309575","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.597","article-title":"Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes","volume":"68","author":"Levelt E","year":"2016","unstructured":"Levelt E, Pavlides M, Banerjee R, et al.. Ectopic and visceral fat deposition in lean and obese patients with type 2 diabetes. J Am Coll Cardiol. 2016, 68:53-63. 10.1016\/j.jacc.2016.03.597","journal-title":"J Am Coll Cardiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/nature04634","article-title":"Reactive oxygen species have a causal role in multiple forms of insulin resistance","volume":"440","author":"Houstis N","year":"2006","unstructured":"Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006, 440:944-8. 10.1038\/nature04634","journal-title":"Nature"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.026609","article-title":"Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity","volume":"10","author":"Timper K","year":"2017","unstructured":"Timper K, Br\u00fcning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech. 2017, 10:679-89. 10.1242\/dmm.026609","journal-title":"Dis Model Mech"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104343","article-title":"Mitochondrial dysfunction and type 2 diabetes","volume":"307","author":"Lowell BB","year":"2005","unstructured":"Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005, 307:384-7. 10.1126\/science.1104343","journal-title":"Science"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/nature08780","article-title":"Circulating mitochondrial DAMPs cause inflammatory responses to injury","volume":"464","author":"Zhang Q","year":"2010","unstructured":"Zhang Q, Raoof M, Chen Y, et al.. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010, 464:104-7. 10.1038\/nature08780","journal-title":"Nature"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1980","article-title":"Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome","volume":"12","author":"Nakahira K","year":"2011","unstructured":"Nakahira K, Haspel JA, Rathinam VA, et al.. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011, 12:222-30. 10.1038\/ni.1980","journal-title":"Nat Immunol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10030414","article-title":"Common and novel markers for measuring inflammation and oxidative stress ex vivo in research and clinical practice\u2014which to use regarding disease outcomes?","volume":"10","author":"Menzel A","year":"2021","unstructured":"Menzel A, Samouda H, Dohet F, Loap S, Ellulu MS, Bohn T. Common and novel markers for measuring inflammation and oxidative stress ex vivo in research and clinical practice\u2014which to use regarding disease outcomes?. Antioxidants (Basel). 2021, 10:414. 10.3390\/antiox10030414","journal-title":"Antioxidants (Basel)"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02126","article-title":"How C-reactive protein structural isoforms with distinctive bioactivities affect disease progression","volume":"11","author":"Rajab IM","year":"2020","unstructured":"Rajab IM, Hart PC, Potempa LA. How C-reactive protein structural isoforms with distinctive bioactivities affect disease progression. Front Immunol. 2020, 11:2126. 10.3389\/fimmu.2020.02126","journal-title":"Front Immunol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/jhh.2010.91","article-title":"The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"25","author":"Lakoski SG","year":"2011","unstructured":"Lakoski SG, Cushman M, Siscovick DS, Blumenthal RS, Palmas W, Burke G, Herrington DM. The relationship between inflammation, obesity and risk for hypertension in the Multi-Ethnic Study of Atherosclerosis (MESA). J Hum Hypertens. 2011, 25:73-9. 10.1038\/jhh.2010.91","journal-title":"J Hum Hypertens"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2020.07.012","article-title":"Associations of GlycA and high-sensitivity C-reactive protein with measures of lipolysis in adults with obesity","volume":"14","author":"Levine JA","year":"2020","unstructured":"Levine JA, Han JM, Wolska A, et al.. Associations of GlycA and high-sensitivity C-reactive protein with measures of lipolysis in adults with obesity. J Clin Lipidol. 2020, 14:667-74. 10.1016\/j.jacl.2020.07.012","journal-title":"J Clin Lipidol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-10184-x","article-title":"Association of C reactive protein triglyceride glucose index with mortality in coronary heart disease and type 2 diabetes from NHANES data","volume":"15","author":"Tang N","year":"2025","unstructured":"Tang N, Chen X, Li H, et al.. Association of C reactive protein triglyceride glucose index with mortality in coronary heart disease and type 2 diabetes from NHANES data. Sci Rep. 2025, 15:24687. 10.1038\/s41598-025-10184-x","journal-title":"Sci Rep"},{"key":"ref56","article-title":"High-sensitivity C-reactive protein: clinical importance","volume":"29","author":"Bassuk SS","year":"2004","unstructured":"Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 2004, 29:439-93.","journal-title":"Curr Probl Cardiol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2022.06.004","article-title":"Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography","volume":"252","author":"Mohebi R","year":"2022","unstructured":"Mohebi R, McCarthy CP, Gaggin HK, van Kimmenade RR, Januzzi JL. Inflammatory biomarkers and risk of cardiovascular events in patients undergoing coronary angiography. Am Heart J. 2022, 252:51-9. 10.1016\/j.ahj.2022.06.004","journal-title":"Am Heart J"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar N","year":"2012","unstructured":"Sarwar N, Butterworth AS, Freitag DF, et al.. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet. 2012, 379:1205-13. 10.1016\/S0140-6736(11)61931-4","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034123","article-title":"Plasma biomarkers of cardiovascular risk in the Framingham Heart Study","volume":"138","author":"Ho JE","year":"2018","unstructured":"Ho JE, Larson MG, Ghorbani A. Plasma biomarkers of cardiovascular risk in the Framingham Heart Study. Circulation. 2018, 138:1-10. 10.1161\/CIRCULATIONAHA.118.034123","journal-title":"Circulation"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2016.08.010","article-title":"Lipidomics: techniques, applications, and outcomes related to biomedical sciences","volume":"41","author":"Yang K","year":"2016","unstructured":"Yang K, Han X. Lipidomics: techniques, applications, and outcomes related to biomedical sciences. Trends Biochem Sci. 2016, 41:954-69. 10.1016\/j.tibs.2016.08.010","journal-title":"Trends Biochem Sci"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S475102","article-title":"The increasing diagnostic role of exosomes in inflammatory diseases to leverage the therapeutic biomarkers","volume":"17","author":"Wang Y","year":"2024","unstructured":"Wang Y, Ma H, Zhang X, Xiao X, Yang Z. The increasing diagnostic role of exosomes in inflammatory diseases to leverage the therapeutic biomarkers. J Inflamm Res. 2024, 17:5005-24. 10.2147\/JIR.S475102","journal-title":"J Inflamm Res"},{"key":"ref62","article-title":"An update on the role of 18F-FDG-PET\/CT in major infectious and inflammatory diseases","volume":"9","author":"Kung BT","year":"2019","unstructured":"Kung BT, Seraj SM, Zadeh MZ, et al.. An update on the role of 18F-FDG-PET\/CT in major infectious and inflammatory diseases. Am J Nucl Med Mol Imaging. 2019, 9:255-73.","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeaf019","article-title":"Characterizing cardiac adipose tissue in post-acute myocardial infarction patients via CT imaging: a comparative cross-sectional study","volume":"26","author":"Wang X","year":"2025","unstructured":"Wang X, Leng S, Adamson PD, et al.. Characterizing cardiac adipose tissue in post-acute myocardial infarction patients via CT imaging: a comparative cross-sectional study. Eur Heart J Cardiovasc Imaging. 2025, 26:733-40. 10.1093\/ehjci\/jeaf019","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01115-3","article-title":"Association of glucose uptake of visceral fat and acute myocardial infarction: a pilot (18)F-FDG PET\/CT study","volume":"19","author":"Pahk K","year":"2020","unstructured":"Pahk K, Kim EJ, Joung C, Seo HS, Kim S. Association of glucose uptake of visceral fat and acute myocardial infarction: a pilot (18)F-FDG PET\/CT study. Cardiovasc Diabetol. 2020, 19:145. 10.1186\/s12933-020-01115-3","journal-title":"Cardiovasc Diabetol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040632","article-title":"Metabolic imaging in non-alcoholic fatty liver disease: applications of magnetic resonance spectroscopy","volume":"10","author":"Thiagarajan P","year":"2021","unstructured":"Thiagarajan P, Bawden SJ, Aithal GP. Metabolic imaging in non-alcoholic fatty liver disease: applications of magnetic resonance spectroscopy. J Clin Med. 2021, 10:632. 10.3390\/jcm10040632","journal-title":"J Clin Med"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.06.005","article-title":"Assessment of hepatic mitochondrial oxidation and pyruvate cycling in NAFLD by (13)C magnetic resonance spectroscopy","volume":"24","author":"Petersen KF","year":"2016","unstructured":"Petersen KF, Befroy DE, Dufour S, Rothman DL, Shulman GI. Assessment of hepatic mitochondrial oxidation and pyruvate cycling in NAFLD by (13)C magnetic resonance spectroscopy. Cell Metab. 2016, 24:167-71. 10.1016\/j.cmet.2016.06.005","journal-title":"Cell Metab"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1625","article-title":"Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study","volume":"63","author":"Lowe G","year":"2014","unstructured":"Lowe G, Woodward M, Hillis G, et al.. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: the ADVANCE study. Diabetes. 2014, 63:1115-23. 10.2337\/db12-1625","journal-title":"Diabetes"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94995-8","article-title":"Inflammatory markers and risk of cardiovascular mortality in relation to diabetes status in the HUNT study","volume":"11","author":"L\u00f8fblad L","year":"2021","unstructured":"L\u00f8fblad L, Hov GG, \u00c5sberg A, Videm V. Inflammatory markers and risk of cardiovascular mortality in relation to diabetes status in the HUNT study. Sci Rep. 2021, 11:15644. 10.1038\/s41598-021-94995-8","journal-title":"Sci Rep"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-124","article-title":"A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial","volume":"10","author":"Mehta NN","year":"2012","unstructured":"Mehta NN, Heffron SP, Patel PN, et al.. A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial. J Transl Med. 2012, 10:124. 10.1186\/1479-5876-10-124","journal-title":"J Transl Med"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01409-0","article-title":"Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes","volume":"20","author":"Sharif S","year":"2021","unstructured":"Sharif S, Van der Graaf Y, Cramer MJ, Kapelle LJ, de Borst GJ, Visseren FL, Westerink J. Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes. Cardiovasc Diabetol. 2021, 20:220. 10.1186\/s12933-021-01409-0","journal-title":"Cardiovasc Diabetol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-4-28","article-title":"Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study","volume":"4","author":"Dallmeier D","year":"2012","unstructured":"Dallmeier D, Larson MG, Vasan RS, et al.. Metabolic syndrome and inflammatory biomarkers: a community-based cross-sectional study at the Framingham Heart Study. Diabetol Metab Syndr. 2012, 4:28. 10.1186\/1758-5996-4-28","journal-title":"Diabetol Metab Syndr"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02446-6","article-title":"Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups","volume":"20","author":"Georgakis MK","year":"2022","unstructured":"Georgakis MK, Malik R, Richardson TG, et al.. Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups. BMC Med. 2022, 20:245. 10.1186\/s12916-022-02446-6","journal-title":"BMC Med"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0369-6","article-title":"Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes","volume":"15","author":"Odegaard AO","year":"2016","unstructured":"Odegaard AO, Jacobs DR Jr, Sanchez OA, Goff DC Jr, Reiner AP, Gross MD. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol. 2016, 15:51. 10.1186\/s12933-016-0369-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112906","article-title":"The role of inflammation in cardiovascular disease","volume":"23","author":"Henein MY","year":"2022","unstructured":"Henein MY, Vancheri S, Longo G, Vancheri F. The role of inflammation in cardiovascular disease. Int J Mol Sci. 2022, 23:12906. 10.3390\/ijms232112906","journal-title":"Int J Mol Sci"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12862","article-title":"Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials","volume":"285","author":"Ridker PM","year":"2019","unstructured":"Ridker PM. Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials. J Intern Med. 2019, 285:503-9. 10.1111\/joim.12862","journal-title":"J Intern Med"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif JC","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, et al.. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019, 381:2497-505. 10.1056\/NEJMoa1912388","journal-title":"N Engl J Med"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-23-00460","article-title":"Dynamic coronary roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial","volume":"20","author":"Hennessey B","year":"2024","unstructured":"Hennessey B, Danenberg H, De Vroey F, et al.. Dynamic coronary roadmap versus standard angiography for percutaneous coronary intervention: the randomised, multicentre DCR4Contrast trial. EuroIntervention. 2024, 20:e198-206. 10.4244\/EIJ-D-23-00460","journal-title":"EuroIntervention"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014741","article-title":"Interleukin\u2010receptor antagonist and tumor necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases","volume":"2021","author":"Mart\u00ed-Carvajal AJ","year":"2021","unstructured":"Mart\u00ed-Carvajal AJ, De Sanctis JB, Dayer M, et al.. Interleukin\u2010receptor antagonist and tumor necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev. 2021, 2021:CD014741. 10.1002\/14651858.CD014741","journal-title":"Cochrane Database Syst Rev"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2019.06.003","article-title":"The low dose colchicine after myocardial infarction (Lodoco-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction","volume":"215","author":"Hennessy T","year":"2019","unstructured":"Hennessy T, Soh L, Bowman M, Kurup R, Schultz C, Patel S, Hillis GS. The low dose colchicine after myocardial infarction (Lodoco-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am Heart J. 2019, 215:62-9. 10.1016\/j.ahj.2019.06.003","journal-title":"Am Heart J"},{"key":"ref80","article-title":"Sodium-glucose transport 2 (SGLT2) inhibitors","author":"Padda IS","year":"2025","unstructured":"Padda IS, Mahtani AU, Parmar M. Sodium-glucose transport 2 (SGLT2) inhibitors. StatPearls [Internet]. StatPearls Publishing, Treasure Island; 2025."},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101549","article-title":"Cardiovascular protection by SGLT2 inhibitors - do anti-inflammatory mechanisms play a role?","volume":"64","author":"Elrakaybi A","year":"2022","unstructured":"Elrakaybi A, Laubner K, Zhou Q, Hug MJ, Seufert J. Cardiovascular protection by SGLT2 inhibitors - do anti-inflammatory mechanisms play a role?. Mol Metab. 2022, 64:101549. 10.1016\/j.molmet.2022.101549","journal-title":"Mol Metab"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1038\/83336","article-title":"PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation","volume":"7","author":"Chawla A","year":"2001","unstructured":"Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001, 7:48-52. 10.1038\/83336","journal-title":"Nat Med"},{"key":"ref83","article-title":"Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance","volume":"5","author":"Patsouris D","year":"2004","unstructured":"Patsouris D, M\u00fcller M, Kersten S. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance. Current Opinion in Investigational Drugs. 2004, 5:1045-50.","journal-title":"Current Opinion in Investigational Drugs"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al.. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016, 375:311-22. 10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein HC","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al.. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019, 394:121-30. 10.1016\/S0140-6736(19)31149-3","journal-title":"The Lancet"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet","volume":"368","author":"Estruch R","year":"2013","unstructured":"Estruch R, Ros E, Salas-Salvad\u00f3 J, et al.. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013, 368:1279-90. 10.1056\/NEJMoa1200303","journal-title":"N Engl J Med"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1186\/s12986-025-00947-8","article-title":"The effects of the Mediterranean diet supplemented with olive oils on pro-inflammatory biomarkers and soluble adhesion molecules: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Tehrani SD","year":"2025","unstructured":"Tehrani SD, Ahmadi AR, Sadeghi N, Keshani M. The effects of the Mediterranean diet supplemented with olive oils on pro-inflammatory biomarkers and soluble adhesion molecules: a systematic review and meta-analysis of randomized controlled trials. Nutr Metab (Lond). 2025, 22:52. 10.1186\/s12986-025-00947-8","journal-title":"Nutr Metab (Lond)"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.6473","article-title":"Vegetarian dietary patterns and mortality in Adventist Health Study 2","volume":"173","author":"Orlich MJ","year":"2013","unstructured":"Orlich MJ, Singh PN, Sabat\u00e9 J, et al.. Vegetarian dietary patterns and mortality in Adventist Health Study 2. JAMA Intern Med. 2013, 173:1230-8. 10.1001\/jamainternmed.2013.6473","journal-title":"JAMA Intern Med"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2008.04.005","article-title":"Association between dietary fiber and markers of systemic inflammation in the Women's Health Initiative Observational Study","volume":"24","author":"Ma Y","year":"2008","unstructured":"Ma Y, H\u00e9bert JR, Li W, et al.. Association between dietary fiber and markers of systemic inflammation in the Women's Health Initiative Observational Study. Nutrition. 2008, 24:941-9. 10.1016\/j.nut.2008.04.005","journal-title":"Nutrition"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.309715","article-title":"Gut microbiota in cardiovascular health and disease","volume":"120","author":"Tang WH","year":"2017","unstructured":"Tang WH, Kitai T, Hazen SL. Gut microbiota in cardiovascular health and disease. Circ Res. 2017, 120:1183-96. 10.1161\/CIRCRESAHA.117.309715","journal-title":"Circ Res"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017995","article-title":"Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials","volume":"9","author":"Koutnikova H","year":"2019","unstructured":"Koutnikova H, Genser B, Monteiro-Sepulveda M, Faurie JM, Rizkalla S, Schrezenmeir J, Cl\u00e9ment K. Impact of bacterial probiotics on obesity, diabetes and non-alcoholic fatty liver disease related variables: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2019, 9:e017995. 10.1136\/bmjopen-2017-017995","journal-title":"BMJ Open"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.12701\/jyms.2022.00010","article-title":"Beneficial effects of intermittent fasting: a narrative review","volume":"40","author":"Song DK","year":"2023","unstructured":"Song DK, Kim YW. Beneficial effects of intermittent fasting: a narrative review. J Yeungnam Med Sci. 2023, 40:4-11. 10.12701\/jyms.2022.00010","journal-title":"J Yeungnam Med Sci"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22065","article-title":"Flipping the metabolic switch: understanding and applying the health benefits of fasting","volume":"26","author":"Anton SD","year":"2018","unstructured":"Anton SD, Moehl K, Donahoo WT, et al.. Flipping the metabolic switch: understanding and applying the health benefits of fasting. Obesity (Silver Spring). 2018, 26:254-68. 10.1002\/oby.22065","journal-title":"Obesity (Silver Spring)"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314564","article-title":"Ketone bodies as metabolites and signalling molecules at the crossroad between inflammation and epigenetic control of cardiometabolic disorders","volume":"23","author":"Bendridi N","year":"2022","unstructured":"Bendridi N, Selmi A, Balcerczyk A, Pirola L. Ketone bodies as metabolites and signalling molecules at the crossroad between inflammation and epigenetic control of cardiometabolic disorders. Int J Mol Sci. 2022, 23:14564. 10.3390\/ijms232314564","journal-title":"Int J Mol Sci"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010611-134520","article-title":"Systems pharmacology: network analysis to identify multiscale mechanisms of drug action","volume":"52","author":"Zhao S","year":"2012","unstructured":"Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol. 2012, 52:505-21. 10.1146\/annurev-pharmtox-010611-134520","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1177\/0300060521992981","article-title":"GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-\u03baB signalling pathway","volume":"49","author":"Chen X","year":"2021","unstructured":"Chen X, Huang Q, Feng J, Xiao Z, Zhang X, Zhao L. GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-\u03baB signalling pathway. J Int Med Res. 2021, 49:300060521992981. 10.1177\/0300060521992981","journal-title":"J Int Med Res"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsadv.2022.100246","article-title":"Journey of organ on a chip technology and its role in future healthcare scenario","volume":"9","author":"Singh D","year":"2022","unstructured":"Singh D, Mathur A, Arora S, Roy S, Mahindroo N. Journey of organ on a chip technology and its role in future healthcare scenario. 2022, 9:100246. 10.1016\/j.apsadv.2022.100246"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.08.005","article-title":"Organs-on-a-chip models for biological research","volume":"184","author":"Vunjak-Novakovic G","year":"2021","unstructured":"Vunjak-Novakovic G, Ronaldson-Bouchard K, Radisic M. Organs-on-a-chip models for biological research. Cell. 2021, 184:4597-611. 10.1016\/j.cell.2021.08.005","journal-title":"Cell"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-817202-5.00008-5","article-title":"Heart-on-a-chip","author":"Gaudriault P","year":"2020","unstructured":"Gaudriault P, Fassini D, Homs-Corbera A. Heart-on-a-chip. Organ-on-a-Chip. Hoeng J, Bovard D, Peitsch MC (ed): Academic Press, New York; 2020. 255-93. 10.1016\/B978-0-12-817202-5.00008-5"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19040936","article-title":"Disease modeling using 3D organoids derived from human induced pluripotent stem cells","volume":"19","author":"Ho BX","year":"2018","unstructured":"Ho BX, Pek NM, Soh BS. Disease modeling using 3D organoids derived from human induced pluripotent stem cells. Int J Mol Sci. 2018, 19:936. 10.3390\/ijms19040936","journal-title":"Int J Mol Sci"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1242\/dev.156166","article-title":"Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond","volume":"145","author":"Liu C","year":"2018","unstructured":"Liu C, Oikonomopoulos A, Sayed N, Wu JC. Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond. Development. 2018, 145:dev156166. 10.1242\/dev.156166","journal-title":"Development"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2020.02.011","article-title":"Multi-lineage human iPSC-derived platforms for disease modeling and drug discovery","volume":"26","author":"Sharma A","year":"2020","unstructured":"Sharma A, Sances S, Workman MJ, Svendsen CN. Multi-lineage human iPSC-derived platforms for disease modeling and drug discovery. Cell Stem Cell. 2020, 26:309-29. 10.1016\/j.stem.2020.02.011","journal-title":"Cell Stem Cell"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033084","article-title":"Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction","volume":"7","author":"Schneider HJ","year":"2012","unstructured":"Schneider HJ, Wallaschofski H, V\u00f6lzke H, et al.. Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction. PLoS One. 2012, 7:e33084. 10.1371\/journal.pone.0033084","journal-title":"PLoS One"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S384977","article-title":"Associations of inflammation with risk of cardiovascular and all-cause mortality in adults with hypertension: an inflammatory prognostic scoring system","volume":"15","author":"Cheang I","year":"2022","unstructured":"Cheang I, Zhu X, Lu X, et al.. Associations of inflammation with risk of cardiovascular and all-cause mortality in adults with hypertension: an inflammatory prognostic scoring system. J Inflamm Res. 2022, 15:6125-36. 10.2147\/JIR.S384977","journal-title":"J Inflamm Res"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.125.326720","article-title":"Interorgan crosstalk in heart failure and cardiometabolic diseases: a compendium","volume":"136","author":"Schiattarella GG","year":"2025","unstructured":"Schiattarella GG, Kontaridis MI. Interorgan crosstalk in heart failure and cardiometabolic diseases: a compendium. Circ Res. 2025, 136:1167-9. 10.1161\/CIRCRESAHA.125.326720","journal-title":"Circ Res"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.125.325517","article-title":"Multiorgan imaging for interorgan crosstalk in cardiometabolic diseases","volume":"136","author":"Devesa A","year":"2025","unstructured":"Devesa A, Delgado V, Valkovic L, Lima JA, Nagel E, Ibanez B, Raman B. Multiorgan imaging for interorgan crosstalk in cardiometabolic diseases. Circ Res. 2025, 136:1454-75. 10.1161\/CIRCRESAHA.125.325517","journal-title":"Circ Res"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v16.i4.102390","article-title":"Antidiabetic combination therapy and cardiovascular outcomes: an evidence-based approach","volume":"16","author":"Ganakumar V","year":"2025","unstructured":"Ganakumar V, Fernandez CJ, Pappachan JM. Antidiabetic combination therapy and cardiovascular outcomes: an evidence-based approach. World J Diabetes. 2025, 16:102390. 10.4239\/wjd.v16.i4.102390","journal-title":"World J Diabetes"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2014.08.032","article-title":"Natriuretic peptides and cardio-renal disease","volume":"176","author":"Volpe M","year":"2014","unstructured":"Volpe M. Natriuretic peptides and cardio-renal disease. Int J Cardiol. 2014, 176:630-9. 10.1016\/j.ijcard.2014.08.032","journal-title":"Int J Cardiol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1327205","article-title":"Systemic inflammation among adults with diagnosed and undiagnosed cardiometabolic conditions: a potential missed opportunity for cardiovascular disease prevention","volume":"10","author":"Mainous AG 3rd","year":"2023","unstructured":"Mainous AG 3rd, Sharma P, Jo A. Systemic inflammation among adults with diagnosed and undiagnosed cardiometabolic conditions: a potential missed opportunity for cardiovascular disease prevention. Front Med (Lausanne). 2023, 10:1327205. 10.3389\/fmed.2023.1327205","journal-title":"Front Med (Lausanne)"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-025-06403-9","article-title":"Exploring the shared genetic landscape of diabetes and cardiovascular disease: findings and future implications","volume":"68","author":"Lee H","year":"2025","unstructured":"Lee H, Fernandes M, Lee J, Merino J, Kwak SH. Exploring the shared genetic landscape of diabetes and cardiovascular disease: findings and future implications. Diabetologia. 2025, 68:1087-100. 10.1007\/s00125-025-06403-9","journal-title":"Diabetologia"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-023-01998-y","article-title":"The neutrophil-lymphocyte ratio as a risk factor for all-cause and cardiovascular mortality among individuals with diabetes: evidence from the NHANES 2003-2016","volume":"22","author":"Dong G","year":"2023","unstructured":"Dong G, Gan M, Xu S, Xie Y, Zhou M, Wu L. The neutrophil-lymphocyte ratio as a risk factor for all-cause and cardiovascular mortality among individuals with diabetes: evidence from the NHANES 2003-2016. Cardiovasc Diabetol. 2023, 22:267. 10.1186\/s12933-023-01998-y","journal-title":"Cardiovasc Diabetol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.316065","article-title":"Genetics insights in the relationship between type 2 diabetes and coronary heart disease","volume":"126","author":"Goodarzi MO","year":"2020","unstructured":"Goodarzi MO, Rotter JI. Genetics insights in the relationship between type 2 diabetes and coronary heart disease. Circ Res. 2020, 126:1526-48. 10.1161\/CIRCRESAHA.119.316065","journal-title":"Circ Res"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-025-00227-7","article-title":"Cluster analysis reveals distinct inflammatory phenotypes in cardiometabolic disease","volume":"11","author":"Bianchi J","year":"2025","unstructured":"Bianchi J, Duarte FO, Camillo L, et al.. Cluster analysis reveals distinct inflammatory phenotypes in cardiometabolic disease. Cardiovasc Diabetol Endocrinol Rep. 2025, 11:15. 10.1186\/s40842-025-00227-7","journal-title":"Cardiovasc Diabetol Endocrinol Rep"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2023.100630","article-title":"Second-year results from CINEMA: a novel, patient-centered, team-based intervention for patients with type 2 diabetes or prediabetes at high cardiovascular risk","volume":"17","author":"Neeland IJ","year":"2024","unstructured":"Neeland IJ, Arafah A, Bourges-Sevenier B, et al.. Second-year results from CINEMA: a novel, patient-centered, team-based intervention for patients with type 2 diabetes or prediabetes at high cardiovascular risk. Am J Prev Cardiol. 2024, 17:100630. 10.1016\/j.ajpc.2023.100630","journal-title":"Am J Prev Cardiol"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.2854","article-title":"Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial","volume":"329","author":"Pagidipati NJ","year":"2023","unstructured":"Pagidipati NJ, Nelson AJ, Kaltenbach LA, et al.. Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial. JAMA. 2023, 329:1261-70. 10.1001\/jama.2023.2854","journal-title":"JAMA"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy JA","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJA, et al.. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005, 366:1279-89. 10.1016\/S0140-6736(05)67528-9","journal-title":"Lancet"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan WN","year":"2016","unstructured":"Kernan WN, Viscoli CM, Furie KL, et al.. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016, 374:1321-31. 10.1056\/NEJMoa1506930","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/421153-metabolic-inflammation-as-a-common-thread-in-cardio-endocrine-diseases-toward-a-unified-therapeutic-framework","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T18:00:14Z","timestamp":1769191214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/421153-metabolic-inflammation-as-a-common-thread-in-cardio-endocrine-diseases-toward-a-unified-therapeutic-framework"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":121,"URL":"https:\/\/doi.org\/10.7759\/cureus.102160","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}